MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Medical Trial of MYMD-1 as a Treatment for Delaying Aging and Increasing Healthy And Balanced Lifespan
MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals (” MyMD” or “the Company”), a scientific stage pharmaceutical firm devoted to extending healthy and balanced life expectancy, today announced that the first person has actually been registered in the Firm’s Stage 2 scientific test of lead prospect MYMD-1, a dental immune regulatory authority drug, as a treatment for delaying aging and also broadening healthy life-span.
The primary endpoint for the Phase 2 double-blind, placebo-controlled professional trial is to achieve a decrease in the flowing levels of (TNF-α), tumor necrosis element receptor I (TNFRI) as well as IL-6. TNF-α as well as IL-6 are the healthy proteins in the body that create inflammation and also help trigger the procedure of aging. The second actions of the trial will certainly be the safety and security, tolerability, and pharmacokinetics in this populace of patients.
” In a Stage 1 clinical trial of MYMD-1, we demonstrated the medicine’s statistically significant efficacy in decreasing levels of TNF-α, a key player in causing pathological aging, in the blood. The FDA has actually authorized TNF-α decrease as the main endpoint for our Stage 2 research study, which we believe settings us well for an effective Stage 2 outcome,” said Chris Chapman, M.D., Head Of State, Supervisor and also Chief Medical Officer of MyMD. “The initiation of client registration in this study breakthroughs our objective to reduce the aging procedure, protect against loss of muscle mass cells in aging, limitation frailty, and also extend healthy lifespan.”
MyMD has actually mentioned that there are no FDA-approved drugs for treating aging conditions and also prolonging healthy and balanced life-span humans, a market expected to be at least $600 billion by 20251 according to a major investment bank. TNF-α blockers are one of the most recommended medicines by revenue, a global market of approximately $40 billion per year,2 as well as, according to Nature Aging journal,3 a downturn in aging that would boost life expectancy by one year is worth $38 trillion and by 10 years is worth $367 trillion.
In addition to aging, MYMD-1’s distinctive action in managing the body immune system and treating persistent inflammation is being developed for the treatment of autoimmune illness, including rheumatoid arthritis (RA), numerous sclerosis (MS), diabetes mellitus, and also inflammatory bowel disease.
” We mean to begin writing procedures for a Stage 2 pilot research of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman noted. “The climbing frequency of rheumatoid joint inflammation as well as other autoimmune as well as inflammatory diseases are driving demand for TNF preventions like MYMD-1, and we believe our orally provided drug with extremely reduced poisoning would certainly be disruptive to the $60 billion market for RA if approved by the FDA for this sign.”
Rheumatoid joint inflammation impacts approximately 40 million individuals around the world.4.
Initially created for autoimmune conditions, MYMD-1’s primary purpose is to reduce the aging procedure, avoid sarcopenia as well as frailty, as well as expand healthy and balanced life-span. Due to the fact that it can go across the blood-brain obstacle and access to the main nerve system (CNS), MYMD-1 is likewise positioned to be a feasible treatment for brain-related problems. Its device of activity and also efficiency in illness including several sclerosis (MS) and thyroiditis have been examined through collaborations with a number of scholastic establishments. MYMD-1 is additionally showing pledge in pre-clinical research studies as a prospective therapy for blog post- COVID-19 problems and also as an anti-fibrotic and anti-proliferation therapeutic.
MYMD-1 has actually shown performance in pre-clinical research studies in controling the body immune system by performing as a selective prevention of tumor death factor-alpha (TNF-α), a driver of persistent swelling. Unlike various other treatments, MYMD-1 has actually been shown in these pre-clinical studies to uniquely obstruct TNF-α when it ends up being overactivated in autoimmune diseases as well as cytokine tornados, yet not block it from doing its normal task of being a very first -responder to any regular sort of modest infection. MYMD-1’s convenience of dental application is another differentiator compared to presently readily available TNF-α blockers, every one of which call for delivery by shot or mixture. No accepted TNF prevention has actually ever before been dosed by mouth. In addition, the medication is not immunosuppressive as well as has actually not been shown to trigger the significant adverse effects common with standard treatments that treat swelling.
About MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical phase pharmaceutical business committed to extending healthy lifespan, is concentrated on establishing 2 novel restorative platforms that treat the sources of disease instead of just dealing with the signs and symptoms. MYMD-1 is a medication platform based on a scientific stage small molecule that manages the immune system to manage TNF-α, which drives chronic inflammation, as well as various other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to delay aging, rise durability, and deal with autoimmune illness and COVID-19- connected anxiety. The Business’s 2nd medicine platform, Supera-CBD, is being established to treat chronic pain, dependency as well as epilepsy. Supera-CBD is a novel artificial derivative of cannabidiol (CBD) and also is being established to address and improve upon the quickly expanding CBD market, which includes both FDA authorized drugs as well as CBD products not currently controlled as drugs. For additional information, go to www.mymd.com.